Cancer Drug Endpoints: More Standardization Needed In ctDNA Assessments, US FDA Says

Circulating tumor DNA needs to be prospectively incorporated into trials to assess whether it correlates with long-term outcomes. More standardization in assays and when the biomarker is measured would strengthen analyses of data across studies, FDA officials said.

Boats at dock
More standardization of circulating tumor DNA assessments has the potential to raise all boats in cancer drug development. • Source: Shutterstock

With work ongoing in the oncology community to develop the evidence needed to support circulating tumor DNA as a regulatory efficacy endpoint, one US Food and Drug Administration official is making a plea for standardization.

Developing the evidence needed to support use of a novel endpoint is a “heavy lift” requiring many stakeholders and pooling...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Diversity Action Plans: What To Submit And When

 
• By 

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

More from R&D

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.